Last --
Change Today 0.00 / 0.00%
Volume 0.0
KNMD On Other Exchanges
Symbol
Exchange
NASDAQ GM
All times are local (Market data is delayed by at least 15 minutes).

kinemed inc (KNMD) Snapshot

Open
--
Previous Close
--
Day High
--
Day Low
--
52 Week High
-- - --
52 Week Low
-- - --
Market Cap
--
Average Volume 10 Days
0.0
EPS TTM
--
Shares Outstanding
16.3M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for KINEMED INC (KNMD)

Related News

No related news articles were found.

kinemed inc (KNMD) Related Businessweek News

No Related Businessweek News Found

kinemed inc (KNMD) Details

KineMed, Inc. develops and commercializes proprietary biomarker platform technology. The company focuses on applying its proprietary biomarker platform technology to drug development, prescription, and non-prescription medical diagnostics and the pairing of drugs with diagnostic biomarker tests. It plans to commercialize biomarkers in the areas of muscle biology, fibrotic diseases, neurodegenerative diseases, cardiometabolic diseases, skin care, and cancer. The company was founded in 2001 and is based in Emeryville, California.

49 Employees
Last Reported Date: 06/9/14
Founded in 2001

kinemed inc (KNMD) Top Compensated Officers

Co-Founder, Chairman and Chief Executive Offi...
Total Annual Compensation: --
Co-Founder, Chairman of the Scientific Adviso...
Total Annual Compensation: --
Chief Financial Officer
Total Annual Compensation: --
Chief Operating Officer
Total Annual Compensation: --
Chief Business Officer and Executive Vice Pre...
Total Annual Compensation: --
Compensation as of Fiscal Year 2014.

kinemed inc (KNMD) Key Developments

KineMed Extends Collaboration with Pfizer in Diabetes

KineMed Inc. announced the renewal of a non-exclusive research collaboration with Pfizer Inc. for the advancement of novel approaches in metabolic disease, in particular Type II diabetes. The collaboration employs KineMed's novel dynamic proteomics technology platform to map the impact of potential drug candidates on specific metabolic pathways.

KineMed, Inc. Appoints Patrick Doyle as Chief Business Officer

KineMed, Inc. announced the appointment of Patrick James Doyle as Executive Vice President & Chief Business Officer. Doyle joins KineMed from PPD where he most recently served as Vice President, Strategic Partnerships. At KineMed, Doyle will lead corporate development activities including licensing and strategic partnerships to enable the Company's vision of changing the way decisions are made in healthcare and wellness through the application of its proprietary kinetic proteomics platform and to expand on its legacy of collaborative pharmaceutical relationships to also establish its own pipeline of therapeutic candidates and diagnostic tests. Prior to joining KineMed Doyle was President of Kareus Therapeutics.

KineMed and CHDI Foundation Extend Huntington's Disease Collaboration

KineMed, Inc. and CHDI Foundation, Inc. announced an extension of their collaboration that uses KineMed's translational biomarker platform to characterize and track the pathogenesis of Huntington's disease (HD) and evaluate potentially therapeutic interventions. The initial study identified deficits in microtubule dynamics and altered protein kinetics in the cerebrospinal fluid (CSF) of several HD models. Ongoing work will look to rescue these changes by lowering expression of huntingtin -- the protein that causes HD - through an interventional therapeutic approach. The aim is to identify pharmacodynamic biomarkers that can be used in clinical trials; the continuation of the collaboration will allow the characterization of additional CSF protein markers, increasing the chance of success. There are currently no therapeutics approved that can slow the progression of HD, an inherited neurodegenerative disorder that affects about 30,000 people in the United States, with up to 150,000 additionally at risk of developing the disease. The clinical signs of disease are behavioral, cognitive, and motor impairments that, over the course of the disease, significantly reduce the individual's quality of life and ultimately cause death within 15 to 25 years of overt motor symptom onset.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
KNMD:US $0.00 USD 0.00

KNMD Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for KNMD.
View Industry Companies
 

Industry Analysis

KNMD

Industry Average

Valuation KNMD Industry Range
Price/Earnings -- Not Meaningful
Price/Sales -- Not Meaningful
Price/Book -- Not Meaningful
Price/Cash Flow -- Not Meaningful
TEV/Sales -- Not Meaningful

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact KINEMED INC, please visit www.kinemed.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.